• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Distribution of ciprofloxacin in the isolated rat lung in the presence and absence of tissue oedema.

作者信息

Reinoso R F, Sánchez-Navarro A, Lanao J M

机构信息

Department of Pharmacy and Pharmaceutical Technology, University of Salamanca, Avda. Campo Charro s/n, 37007, Salamanca, Spain.

出版信息

Eur J Pharm Sci. 1999 Jul;8(3):203-9. doi: 10.1016/s0928-0987(99)00011-1.

DOI:10.1016/s0928-0987(99)00011-1
PMID:10379043
Abstract

A series of experiments with the isolated perfused rat lung was carried out to study the distribution of ciprofloxacin in this tissue under different experimental conditions; the influence of drug administration rate and the presence of oedema were evaluated by comparison of the statistical moment and distribution coefficient values as well as the unit disposition function (UDF) profiles in the tissue. The polyexponential character of the outflow perfusate curves indicates a distribution behaviour which does not correspond to the 'well stirred model' but rather to the existence of some type of diffusion barriers and/or tissue binding. The presence of oedema in the tissue, induced by insufficient oxygenation of perfusate, significantly increases the distribution coefficient of ciprofloxacin and leads to relevant modifications in the unit disposition function (UDF) of the isolated lung, while administration rate does not significantly affect the kinetic behaviour of the drug in this tissue.

摘要

相似文献

1
Distribution of ciprofloxacin in the isolated rat lung in the presence and absence of tissue oedema.
Eur J Pharm Sci. 1999 Jul;8(3):203-9. doi: 10.1016/s0928-0987(99)00011-1.
2
Influence of dose on the distribution kinetics of ciprofloxacin and ofloxacin in the isolated hindlimb of the rat.
Biopharm Drug Dispos. 2000 Nov;21(8):313-9. doi: 10.1002/bdd.245.
3
Comparative scintigraphic study of 99mTc ciprofloxacin pharmacokinetics after intravenous and lymphotropic administration in experimental pulmonary suppuration.
Bull Exp Biol Med. 2005 Jan;139(1):94-7. doi: 10.1007/s10517-005-0223-4.
4
Penetration of ciprofloxacin into human lung tissue after oral and i.v. dosing.
J Chemother. 1989 Jul;1(4 Suppl):549-51.
5
Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens.达氟沙星和环丙沙星在肉鸡体内的处置动力学
Dtsch Tierarztl Wochenschr. 2001 Oct;108(10):429-34.
6
Comparative pharmacokinetic disposition of fluoroquinolones in the lung.氟喹诺酮类药物在肺部的比较药代动力学研究
J Antimicrob Chemother. 1991 Dec;28 Suppl C:65-71. doi: 10.1093/jac/28.suppl_c.65.
7
Assessment of antibiotic levels in lung tissue with erosion-controlled dosage forms.
Eur J Drug Metab Pharmacokinet. 1997 Jul-Sep;22(3):237-43. doi: 10.1007/BF03189813.
8
In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation.体外和离体方法预测了脂质体环丙沙星制剂用于雾化时肺部驻留时间的延长。
Eur J Pharm Biopharm. 2014 Jan;86(1):83-9. doi: 10.1016/j.ejpb.2013.06.024. Epub 2013 Jul 10.
9
Population pharmacokinetic modeling to establish the role of P-glycoprotein on ciprofloxacin distribution to lung and prostate following intravenous and intratracheal administration to Wistar rats.应用群体药代动力学模型探究 P-糖蛋白对环丙沙星在 Wistar 大鼠静脉和气管内给药后肺部和前列腺组织分布的影响。
Eur J Pharm Sci. 2019 Jan 15;127:319-329. doi: 10.1016/j.ejps.2018.11.007. Epub 2018 Nov 10.
10
Concentration of ciprofloxacin and metronidazole in human tissues during abdominal surgery.腹部手术期间人体组织中环丙沙星和甲硝唑的浓度。
J Chemother. 1989 Jul;1(4 Suppl):562-4.

引用本文的文献

1
A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics.一个纳入弥散概念的基于生理的全身药代动力学模型:短期和长期特征
J Pharmacokinet Pharmacodyn. 2001 Feb;28(1):27-55. doi: 10.1023/a:1011565602152.